5 Pharmaceutical Stocks to Buy Now

by Portfolio Grader | May 10, 2013 11:16 am

This week, five Pharmaceutical stocks are improving their overall rating on Portfolio Grader[1]. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).

TherapeuticsMD Inc’s (AMEX:TXMD[2]) grade is moving up to a B (“buy”) this week from last week’s C (“hold”). In Portfolio Grader’s specific subcategories of Earnings Momentum and Sales Growth, TXMD also gets A’s. TherapeuticsMD operates as a women’s healthcare product company in the United States. For more information, get Portfolio Grader’s complete analysis of TXMD stock[3].

Johnson & Johnson (NYSE:JNJ[4]) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The stock has a dividend yield of 2.4%. For more information, get Portfolio Grader’s complete analysis of JNJ stock[5].

Bristol-Myers Squibb (NYSE:BMY[6]) improves from a C to a B rating this week. Bristol-Myers Squibb is a global company that develops, produces and sells pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of BMY stock[7].

The rating of Watson Pharmaceuticals (NYSE:WPI[8]) moves up this week, rising from a B to an A. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock[9].

Repros Therapeutics (NASDAQ:RPRX[10]) earns an A this week, jumping up from last week’s grade of B. Repros Therapeutics is a development stage biopharmaceutical company focusing on the development of oral small molecule drugs for major unmet medical needs. For more information, get Portfolio Grader’s complete analysis of RPRX stock[11].

Louis Navellier’s proprietary Portfolio Grader[12] stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here[13].

Endnotes:

  1. Portfolio Grader: https://navelliergrowth.investorplace.com/portfolio-grader/
  2. TXMD: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=TXMD
  3. For more information, get Portfolio Grader’s complete analysis of TXMD stock: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=TXMD
  4. JNJ: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=JNJ
  5. For more information, get Portfolio Grader’s complete analysis of JNJ stock: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=JNJ
  6. BMY: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=BMY
  7. For more information, get Portfolio Grader’s complete analysis of BMY stock: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=BMY
  8. WPI: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=WPI
  9. For more information, get Portfolio Grader’s complete analysis of WPI stock: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=WPI
  10. RPRX: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=RPRX
  11. For more information, get Portfolio Grader’s complete analysis of RPRX stock: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=RPRX
  12. Portfolio Grader: https://navelliergrowth.investorplace.com/portfolio-grader/
  13. here: https://navelliergrowth.investorplace.com/portfolio-grader/

Source URL: https://investorplace.com/2013/05/5-pharmaceutical-stocks-to-buy-now-txmd-jnj-bmy/

Copyright ©2024 InvestorPlace unless otherwise noted.